Literature DB >> 9253620

Tumoral calcinosis: a clinicopathological study of 111 cases with emphasis on the earliest changes.

N M Pakasa1, R M Kalengayi.   

Abstract

AIMS: To study the pathogenesis of tumoral calcinosis (TC), we investigated 111 cases registered in Zaire over 30 years. METHODS AND
RESULTS: The patients were 108 black Africans and three Caucasians between 3 and 74 years of age (mean, 37.7; median, 39). The gender was known in 33 males and 46 females; in 79 the gender was unknown. All but three were healthy and one had tuberculosis. The majority presented with a painless swelling in single or multiple periarticular regions. The hip was the most commonly affected (57%). Seven recurrences after surgical removal of the mass were reported. On microscopic examination, lesions were classified as follows: 24% stage I, 16% stage II and 60% stage III depending on the cellular activity at the border of the cysts. In five stage I cases only, and in no advanced stage II/III lesions, were exuberant cellular proliferative changes seen adjacent to the classical cystic form. These consisted of either ill-defined reactive-like perivascular solid cell nests admixed with mononuclear and iron-loaded macrophages, or well-organized variably sized fibrohistiocytic nodules embedded in a dense collagenous stroma. These immature changes indicated newly appearing lesions and were assumed to represent the earliest discernible stages in the evolution of TC. The unique well-defined fibrohistiocytic nodules have not been described previously.
CONCLUSIONS: These findings have thus described the full spectrum of lesions occurring in TC. We believe that the adjacent findings are potentially important either in recognizing early stages of the disease or in understanding its pathogenesis.

Entities:  

Mesh:

Year:  1997        PMID: 9253620     DOI: 10.1046/j.1365-2559.1997.6050831.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Phosphoglyceride crystal deposition disease presenting as multiple paragastric masses.

Authors:  Shinichi Yachida; Noriyoshi Fukushima; Yukihiro Nakanishi; Satoshi Nimura; Masahiko Sato; Kazuaki Shimada; Katsutoshi Miura; Michiie Sakamoto
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

2.  Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.

Authors:  Q-Y Zuo; X Cao; B-Y Liu; D Yan; Z Xin; X-H Niu; C Li; W Deng; Z-Y Dong; J-K Yang
Journal:  J Endocrinol Invest       Date:  2019-09-18       Impact factor: 4.256

3.  Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family.

Authors:  M F Campagnoli; A Pucci; E Garelli; A Carando; C Defilippi; R Lala; G Ingrosso; I Dianzani; M Forni; U Ramenghi
Journal:  J Clin Pathol       Date:  2006-04       Impact factor: 3.411

Review 4.  Review of tumoral calcinosis: A rare clinico-pathological entity.

Authors:  Ibrahim Fathi; Mahmoud Sakr
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

5.  The idiopathic localized tumoral calcinosis: the "chicken wire" radiographic pattern.

Authors:  Marco Di Serafino; Matilde Gioioso; Rosa Severino; Francesco Lisanti; Rosario Rocca; Paolo Sorbo; Domenico Maroscia
Journal:  Radiol Case Rep       Date:  2017-05-03

Review 6.  Heterotopic ossification: radiological and pathological review.

Authors:  Bilal Mujtaba; Ahmed Taher; Matthew J Fiala; Sameh Nassar; John E Madewell; Abdelrahman K Hanafy; Rizwan Aslam
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

7.  A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.

Authors:  Christopher T Esapa; Rosie A Head; Jeshmi Jeyabalan; Holly Evans; Tertius A Hough; Michael T Cheeseman; Eugene G McNally; Andrew J Carr; Gethin P Thomas; Matthew A Brown; Peter I Croucher; Steve D M Brown; Roger D Cox; Rajesh V Thakker
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.